Eric Nuermberger, MD

Faculty

Titles:

Associate Professor, Medicine

Email:

Eric Nuermberger

SciVal:

SciVal Link

The primary research focus in my laboratory is translational research related to TB drug development. Using established animal and in vitro models of active and latent TB infection and relying on pharmacodynamic principles, our major goal is to identify and optimize new drugs and drug combinations to shorten and/or simplify TB treatment and restrict the emergence of drug resistance. Over the past 15 years, our work has informed the development of a number of new and repurposed drugs, including moxifloxacin, rifapentine, bedaquiline, PA-824, and the oxazolidinones sutezolid and linezolid, as well as novel combinations containing these drugs. We continue to refine existing models and develop new models for pre-clinical drug efficacy studies, including murine models of cavitary TB and a flow-controlled in vitro system for studying the pharmacodynamics of new drugs and combinations.    

A second research interest is applying similar approaches to improve the treatment of Buruli ulcer, an emerging yet neglected tropical disease characterized by enlarging and ultimately disabling skin ulcers caused by infection with Mycobacterium ulcerans and production of its unique cytotoxin mycolactone. Only in the last decade has chemotherapy replaced surgery as the preferred therapeutic option, especially for early lesions. However, early lesions are difficult to detect with available diagnostics and the current regimen of streptomycin and rifampin for 8 weeks has many drawbacks. We aim to translate advances in the TB drug development space and novel ideas for detection of mycolactone in biological samples to improve therapeutics and point-of-care diagnostics.

Categories

Events

«

February 2019

»
S
M
T
W
T
F
S
·
·
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
·
·

Projects

A Nurse Case Management Intervention to...

Dr. Farley is responsible for the overall project from design, implementation, data collection, and preparation of...

Read More

A novel “shock and kill” strategy...

The objective of this study is to determine if pharmacological inhibition of the Mtb stringent response leads to accelerated...

Read More

ACTG trial A5343

Phase 2 safety study of bedaquiline and delamanid for the treatment of MDR-TB in South Africa

Read More

Evaluation of a novel serum biosignature for...

This study will use multiple high-throughput modalities, including LC-MS/MS and RNA-seq, to detect a panel of host metabolites...

Read More

Understanding the costs and...

We have conducted an empirical costing analysis of facility-based versus community-based treatment for TB in Bangladesh and are...

Read More